BIT 225

Drug Profile

BIT 225

Alternative Names: BIT-225; BIT225-009

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biotron
  • Class Antivirals; Guanidines; Naphthalenes; Pyrazoles; Small molecules
  • Mechanism of Action Hepatitis C virus p7 protein inhibitors; Hepatitis C virus replication inhibitors; HIV replication inhibitors; Human immunodeficiency virus 1 vpu protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Phase II Hepatitis C; HIV infections; HIV-1 infections

Most Recent Events

  • 03 Jan 2018 Biotron completes a phase II trial in HIV-1 infections (Treatment-naive, Combination therapy) in Thailand (PO, Capsule) (ACTRN12617000025336)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in Australia (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(In volunteers) in Australia (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top